Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
7 Veni-beurzen voor MDL-onderzoek
aug 2024 | Hepatologie, IBD, Immuuntherapie, Maag-darm-leveroncologie, Pancreatitis, Parasitaire infecties